别嘌呤醇
医学
安慰剂
耐火材料(行星科学)
癫痫
不利影响
麻醉
双盲
交叉研究
内科学
儿科
精神科
天体生物学
物理
病理
替代医学
作者
Giangennaro Coppola,Antonio Pascotto
标识
DOI:10.1016/0387-7604(95)00110-7
摘要
We report the results of a double-blind, placebo-controlled cross-over trial with allopurinol as add-on therapy in childhood refractory epilepsy. Seventeen patients received allopurinol and matched placebo for 12 weeks in 2 doses (10 mg/kg/day during the first week and 15 mg/kg/day thereafter with a washout period of 2 weeks between treatment phases. The total number of seizures was reduced by 50-98% in 4 patients (23.5%) and by 25-49% in another 4 (23.5%). However, the number of seizures remained unchanged in 5 patients (29.4%) and worsened in 4 (23.5%). Adverse side effects (17.6%) were generally mild and transient, suggesting that allopurinol is well-tolerated. A mean follow-up of 10 months of the responders did not show any relevant efficacy of allopurinol as an adjuvant therapy for refractory epilepsy, even at high doses.
科研通智能强力驱动
Strongly Powered by AbleSci AI